Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4848916 | 0.88 | CASP1 (0.55) | GSK3BLMNACASP1TSHRSMN1; SMN2 | |
| SCHEMBL4855871 | 0.85 | GSK3B (0.57) | GSK3BLMNACASP1TSHRMAPT | |
| SCHEMBL4849613 | 0.82 | GSK3B (0.58) | GSK3BLMNACASP1TSHRSMN1; SMN2 | |
| SCHEMBL4856266 | 0.81 | CASP1 (0.69) | GSK3BLMNACASP1TSHRKMT2A | |
| SCHEMBL4856060 | 0.80 | TSHR (0.60) | GSK3BLMNACASP1TSHRKMT2A | |
| SCHEMBL4852979 | 0.79 | CASP1 (0.57) | GSK3BLMNACASP1TSHRSMN1; SMN2 | |
| SCHEMBL13986930 | 0.79 | MCL1 (0.55) | SMN1; SMN2ALDH1A1ERAP1 | |
| SCHEMBL4855185 | 0.76 | GSK3B (0.60) | GSK3BLMNACASP1NPC1RAB9A | |
| SCHEMBL4849100 | 0.75 | MAPT (0.77) | GSK3BLMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4847310 | 0.74 | GSK3B (0.66) | GSK3BLMNACASP1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| EP-1611121-B1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | AVENTIS PHARMA SA (FR) | 2007-08-08 | — | — | EP | disclosed |
| EP-1581505-B1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-01 | — | — | EP | disclosed |
| EP-1611121-A1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | Aventis Pharma S.A. (FR) | 2006-01-04 | — | — | EP | disclosed |
| EP-1581505-A1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
| US-20040176377-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2004046117-A1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004046130-A1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176377-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | ADRA2C, ADRA1A, ADRA1B | GSK3B 3654/4885LMNA 893/4885CASP1 2557/4885 |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | C5, ADRA2C, ADRA1A | GSK3B 3708/4885LMNA 680/4885CASP1 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.